Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL2176024 | 1.00 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL98410 | 0.95 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Hydrochloric Acid SCHEMBL10584588 | 0.94 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Water SCHEMBL27625510 | 0.94 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Pyrophosphoric Acid SCHEMBL2800166 | 0.93 | P2RY6 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Triphosphate SCHEMBL28074755 | 0.91 | P2RY6 (0.49) | P2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL425422 | 0.85 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2176031 | 0.85 | P2RY6 (0.47) | P2RY14P2RY2P2RY6P2RY4 | |
| Phosphoric Acid SCHEMBL21465157 | 0.85 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL18486662 | 0.84 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080150-A | Mutant of L protein of rift valley fever virus and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-3538151-B1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INST BIOMEDICAL RES (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11993794-B2 | Methods to create chemically-induced dimerizing protein systems for regulation of cellular events | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-28 | — | — | US | disclosed |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| CN-112679480-B | Preparation method of tegafur | 鲁南制药集团股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-112759579-B | Preparation method of antitumor drug tegafur | 鲁南制药集团股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-116850278-A | RNA adjuvant capable of controllably loading therapeutic nucleoside analogues and preparation method and application thereof | 上海交通大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-116270509-A | Orally disintegrating preparation containing tegafur, gimeracil and octreotide potassium | 郑州大学第一附属医院 | 2023-06-23 | — | — | CN | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| WO-2005051452-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051316-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051483-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005046516-A2 | MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046746-A2 | MEDICAL IMPLANTS AND FIBROSIS-INDUCING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046747-A2 | INTRAVASCULAR DEVICES AND FIBROSIS-INDUCING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005044142-A2 | INTRAVASCULAR DEVICES AND FIBROSIS-INDUCING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20040265368-A1 | Combination compositions of camptothecins and fluoropyrimidines | CELATOR PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004087115-A2 | COMBINATION COMPOSITIONS OF CAMPTOTHECINS AND FLUOROPYRIMIDINES | CELATOR PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087105-A1 | COMBINATION FORMULATIONS OF PLATINUM AGENTS AND FLUOROPYRIMIDINES | CELATOR PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | SLC28A1 18/4885SLC28A2 14/4885SLC29A1 2/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | SLC28A1 18/4885SLC28A2 15/4885SLC29A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.